SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:2cb7bff0-127e-4775-8dd8-f43de871b21b"
 

Search: onr:"swepub:oai:lup.lub.lu.se:2cb7bff0-127e-4775-8dd8-f43de871b21b" > Prevention of thali...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Palumbo, A. (author)

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2007-12-20
  • Springer Science and Business Media LLC,2008

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:2cb7bff0-127e-4775-8dd8-f43de871b21b
  • https://lup.lub.lu.se/record/1196431URI
  • https://doi.org/10.1038/sj.leu.2405062DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The incidence of venous thromboembolism (VTE) is more than 1%omicron annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy. Various VTE prophylaxis strategies, such as low-molecular-Weight heparin (LMWH), warfarin or aspirin, have been investigated in small, uncontrolled clinical studies. This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model. Individual risk factors for thrombosis associated with thalidomide/lenalidomide-based therapy include age, history of VTE, central venous catheter, comorbidities (infections, diabetes, cardiac disease), immobilization, surgery and inherited thrombophilia. Myeloma-related risk factors include diagnosis and hyperviscosity. VTE is very high in patients who receive high-dose dexamethasone, doxorubicin or multiagent chemotherapy in combination with thalidomide or lenalidomide, but not with bortezomib. The panel recommends aspirin for patients with <= 1 risk factor for VTE. LMWH (equivalent to enoxaparin 40 mg per day) is recommended for those with two or more individual/myeloma-related risk factors. LMWH is also recommended for all patients receiving concurrent high-dose dexamethasone or doxorubicin. Full-dose warfarin targeting a therapeutic INR of 2-3 is an alternative to LMWH, although there are limited data in the literature with this strategy. In the absence of clear data from randomized studies as a foundation for recommendations, many of the following proposed strategies are the results of common sense or derive from the extrapolation of data from many studies not specifically designed to answer these questions. Further investigation is needed to define the best VTE prophylaxis.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Rajkumar, S. V. (author)
  • Dimopoulos, M. A. (author)
  • Richardson, P. G. (author)
  • Miguel, J. San (author)
  • Barlogie, B. (author)
  • Harousseau, J. (author)
  • Zonder, J. A. (author)
  • Cavo, M. (author)
  • Zangari, M. (author)
  • Attal, M. (author)
  • Belch, A. (author)
  • Knop, S. (author)
  • Joshua, D. (author)
  • Sezer, O. (author)
  • Ludwig, H. (author)
  • Vesole, D. (author)
  • Blade, J. (author)
  • Kyle, R. (author)
  • Westin, JanLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)med-jwe (author)
  • Weber, D. (author)
  • Bringhen, S. (author)
  • Niesvizky, R. (author)
  • Waage, A. (author)
  • von Lilienfeld-Toal, M. (author)
  • Lonial, S. (author)
  • Morgan, G. J. (author)
  • Orlowski, R. Z. (author)
  • Shimizu, K. (author)
  • Anderson, K. C. (author)
  • Boccadoro, M. (author)
  • Durie, B. G. (author)
  • Sonneveld, P. (author)
  • Hussein, M. A. (author)
  • Stamcellscentrum (SCC)Avdelningen för stamcellsforskning (creator_code:org_t)

Related titles

  • In:Leukemia: Springer Science and Business Media LLC22:2, s. 414-4231476-55510887-6924

Internet link

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view